Briumvi 150 mg concentrate for solution for infusion clinical trials

A Phase 2, Open-Label, Randomized, Multicenter Study of KYV101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T Cell (CD19 CAR T) Therapy, in Subjects with Refractory Primary and Secondary Progressive Multiple Sclerosis (KYSA-7)

This study is testing a new type of cell therapy called KYV101 for people with serious forms of multiple sclerosis (MS) that are getting worse. It compares this new treatment with existing MS medications to see how well it works and if it's safe.